Granules India acquires Auctus Pharma for $20 million
Posted on November 5, 2013
Hyderabad-based mid-sized pharmaceutical firm Granules India has acquired Auctus Pharma in an all-cash deal worth $20 million (Rs 120 crore).
Hyderabad-based Auctus Pharma is Granules’ first-ever acquisition and operates as a separate division initially. Granules has said that the company will fund 20 percent of the deal amount through internal accruals and the rest through debt.
Mr V V S Murthy, chief financial officer of Granules, said that Granules will effectively save at least four-to-five years by acquiring Auctus Pharma, which possesses US food and drug administration (FDA) and WHO-GMP approved facilities.
Granules’ managing director Mr Krishna Prasad said that the acquisition was a right fit and helped the company to diversify its product portfolio.
Auctus Pharma, which reported $20 million (Rs 120 crore) of revenue last fiscal, has two manufacturing facilities, including a US FDA-approved active pharmaceutical ingredients (API) facility at Visakhapatnam and an intermediates facility in Hyderabad. Its product portfolio includes 12 active pharmaceutical ingredients and key intermediates.
Related Topics and Keywords
Auctus Pharma, FDA, Granules India, WHO
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy















